Browse the evidence

Concomitant use of linaclotide is associated with significantly greater weight loss in patients taking semaglutide, whereas diabetes mellitus and dulaglutide use are associated with reduced efficacy.

If you are taking semaglutide, your other medications matter. Taking linaclotide (for constipation/IBS) is associated with better weight loss results, while taking diabetes medications like dulaglutide or metformin, or having a diabetes diagnosis, is associated with less weight loss. This suggests that your specific health profile and other drugs significantly influence semaglutide's effectiveness.

Oral semaglutide at 50 mg once daily achieves significantly greater HbA1c reduction (2.1%) and weight loss (9.8%) compared to the approved 14 mg dose, with higher discontinuation rates due to gastrointestinal adverse events.

If you have Type 2 Diabetes and struggle with blood sugar or weight, oral semaglutide 50mg is a potent non-injectable option. It works better than the standard 14mg dose, lowering HbA1c by 2.1% and causing nearly 10% weight loss. However, be prepared for potential stomach issues like nausea, which are common but usually mild. Take it on an empty stomach with a small sip of water as directed.

Short-term time-restricted eating (8-hour window) improves 24-hour glucose homeostasis (reduced area under the curve) compared to an extended 12-hour eating window, despite identical food intake.

Compressing your eating window to 8 hours (e.g., 10 AM to 6 PM) can significantly improve your daily blood glucose control, even if you eat the exact same amount of food as you would over 12 hours. This is achieved by shifting meal times to delay breakfast and finish dinner earlier, which helps manage glucose spikes.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces significant, dose-dependent weight loss (8.5–8.8%) in adults with obesity at doses of 24–36 mg/day, with gastrointestinal side effects being the primary limiting factor.

Take orforglipron once daily. Start at a low dose (6-9 mg) and increase to 12 mg, then to 24-36 mg as tolerated. Expect 8-9% body weight loss over 6 months. Manage nausea by titrating slowly.

Dual agonists of GLP-1 and glucagon (GCGR) or GIP receptors provide greater weight loss and broader metabolic benefits than mono-agonists, potentially addressing treatment barriers like cost and access by treating non-cardiometabolic complications.

If you have obesity, especially with related conditions like diabetes or fatty liver, newer dual-agonist medications (like tirzepatide) may offer significantly greater weight loss and health benefits than older drugs. However, access is currently limited by cost and insurance coverage. Discuss these options with your doctor, focusing on how treating multiple complications might justify the expense.

Unimolecular dual-agonists targeting GLP-1 and GIP receptors (e.g., tirzepatide) provide superior glycemic control and weight loss compared to GLP-1 receptor agonists alone by leveraging additive insulinotropic effects and distinct metabolic pathways.

If you have Type 2 Diabetes and struggle with weight, dual-agonist medications (like tirzepatide) may offer better blood sugar control and weight loss than older GLP-1 drugs. These medications work by mimicking gut hormones to boost insulin, reduce appetite, and increase energy expenditure. While they are injections and may cause temporary nausea, the clinical benefits for metabolic health are significant. Consult your doctor to see if this advanced therapy is appropriate for your specific health profile.

GLP-1 receptor agonists (GLP-1RAs) effectively manage type 2 diabetes and obesity by mimicking endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, and promote satiety through delayed gastric emptying and hypothalamic signaling.

GLP-1 receptor agonists are a proven treatment for Type 2 Diabetes and obesity. They work by mimicking a natural hormone to help your pancreas release insulin when needed, stop the release of sugar-storing hormones, and make you feel full faster. This leads to better blood sugar control and weight loss. While they are effective, they require injections, which can be a barrier for some patients.

GLP-1 receptor agonists induce significant fat mass loss with a non-significant or significantly smaller reduction in muscle mass, resulting in muscle mass accounting for less than 20% of total weight loss.

If you are taking a GLP-1 medication like Ozempic or Wegovy, your body is prioritizing fat loss over muscle loss. While you may lose a small amount of muscle, it is a minor fraction of your total weight loss (under 20%). Focus on maintaining strength through resistance training to preserve the muscle you have, but do not let fear of muscle loss stop you from using effective weight management tools.

Performing bariatric surgery during the pre-diabetic or early diabetic stages significantly reduces the incidence of type 2 diabetes and promotes remission, whereas delaying surgery until advanced stages with established complications yields minimal metabolic benefit and higher mortality risk.

If you have obesity and type 2 diabetes (or pre-diabetes), do not wait until your condition is severe or you have complications like kidney or eye damage. Seek bariatric surgery evaluation early. The evidence shows that operating while your diabetes is new or in the pre-diabetic stage offers the highest chance of reversing the disease and preventing long-term damage, whereas waiting until the disease is advanced often fails to provide survival or health benefits.

GLP-1 receptor agonists (GLP-1RAs) and dual/triple incretin agonists produce clinically relevant hepatic improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH), including MASH resolution, liver fat reduction, and prevention of fibrosis worsening.

If you have MASH or MASLD, especially with obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a valuable treatment option. They not only help with weight and blood sugar but also directly improve liver health by reducing fat and inflammation. While lifestyle changes remain important, these medications can help achieve the necessary weight loss (7-10%) if you struggle to do so alone. Discuss these options with your gastroenterologist.

Among GLP-1 receptor agonists, tirzepatide induces the greatest reduction in body mass index (BMI), while orforglipron demonstrates the strongest benefit in lowering systolic blood pressure.

Not all GLP-1 drugs are equal for every health goal. If your primary concern is significant weight loss, tirzepatide shows the greatest BMI reduction in this analysis. If high blood pressure is the main issue, orforglipron showed the strongest blood pressure-lowering effect. Consult your doctor to choose the agent that best targets your specific cardiometabolic risks.

GLP-1 receptor agonist therapies significantly reduce C-reactive protein (CRP) levels, with semaglutide showing the most efficacious reduction compared to other agents.

GLP-1 therapies also help reduce systemic inflammation, as measured by C-reactive protein (CRP). Semaglutide was found to be particularly effective at lowering CRP levels, which may contribute to its cardiovascular benefits.

GLP-1 receptor agonists (specifically liraglutide) significantly reduce body weight and improve cardiometabolic risk factors (BMI, fasting plasma glucose, lipid profile) in obese or overweight individuals with psychotic disorders treated with antipsychotic drugs.

For patients with psychotic disorders on antipsychotics who struggle with obesity, GLP-1 receptor agonists (especially liraglutide) are a proven, effective treatment for weight loss and improving metabolic health. They significantly reduce body weight, BMI, and improve blood sugar and lipid levels without increasing the risk of stopping treatment compared to standard care. Liraglutide appears more effective than exenatide for weight loss in this group.

GLP-1 receptor agonists significantly improve lipid profiles (reducing Total Cholesterol and LDL-C, increasing HDL-C) and fasting plasma glucose in obese individuals with psychotic disorders, but do not significantly affect waist circumference, systolic/diastolic blood pressure, or triglycerides.

GLP-1 receptor agonists improve blood sugar and cholesterol levels (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with psychotic disorders, but they do not significantly lower blood pressure or waist circumference. This makes them valuable for metabolic health, even if blood pressure remains unchanged.

Meeting multiple glycemic criteria (IFG, IGT, and/or elevated HbA1c) for prediabetes significantly increases the risk of progressing to type 2 diabetes compared to meeting only one criterion.

If you have prediabetes, ask your doctor to check all three glycemic markers (fasting glucose, 2-hour post-meal glucose, and HbA1c). Meeting more than one abnormal result means your risk of developing type 2 diabetes is much higher, and you should prioritize intensive lifestyle changes or discuss medication with your provider immediately.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.

If you have Type 2 Diabetes or obesity, Tirzepatide is a once-weekly injection that lowers blood sugar and reduces body weight more effectively than current GLP-1 drugs (like semaglutide) or insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects are gastrointestinal, but they often decrease over time. Consult a doctor to see if you are a candidate.

GLP-1 receptor agonists (e.g., liraglutide) induce weight loss primarily by targeting brainstem circuits (specifically the area postrema) rather than mimicking natural gut signals, as natural GLP-1 levels do not regulate body weight.

GLP-1 drugs work by targeting the brainstem to reduce food intake, not by mimicking natural gut signals. This is a distinct mechanism from natural satiety.

Current GLP-1-based anti-obesity medications (AOMs) achieve profound acute body weight loss (up to 25%) but are associated with significant real-world treatment discontinuation (up to 50%) due to gastrointestinal side effects and lack of lifestyle counseling, necessitating novel formulations with improved tolerability.

While GLP-1 drugs like semaglutide and tirzepatide produce significant weight loss, real-world adherence is a major hurdle due to gastrointestinal side effects. To maximize success, patients should utilize flexible, patient-determined titration schedules rather than fixed rapid escalation, and consider prophylactic anti-emetics if needed, as these strategies improve long-term tolerability and adherence.

Anti-obesity medications (AOMs) such as GLP-1 receptor agonists do not render lifestyle-based treatments obsolete; rather, they act synergistically by addressing physiological barriers to weight loss, allowing behavioral interventions to focus on optimizing body composition and long-term health maintenance.

Do not stop your lifestyle efforts when starting medication. Use the medication to manage hunger and physiological resistance, then redirect that energy into building fitness, muscle mass, and healthy eating habits. The medication handles the biology; you handle the lifestyle optimization for long-term health.

High body mass index (BMI) and visceral adiposity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).

Maintaining a healthy weight is critical for kidney health. High BMI and visceral fat directly damage kidneys through increased pressure and hormonal imbalances, leading to chronic kidney disease. While weight loss in advanced kidney disease is complex, preventing obesity is the most effective way to protect your kidneys from long-term damage.

Obesity is associated with a significantly increased risk of kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers.

Obesity increases your risk of developing kidney cancer. Maintaining a healthy weight can help reduce this risk.

Insulin resistance (IR) and the resulting hyperinsulinemia constitute the primary shared pathogenic mechanism linking metabolic syndrome, obesity, and type 2 diabetes (T2DM), driving cardiovascular disease (CVD) risk through prothrombotic effects, endothelial dysfunction, and atherogenic dyslipidemia.

Focus on improving insulin sensitivity through lifestyle changes rather than assuming disease is inevitable due to family history. Managing insulin levels via diet and activity can mitigate the risk of cardiovascular complications associated with metabolic syndrome and obesity.

Increased circulating levels of branched-chain amino acids (BCAAs) and imidazole propionate, linked to gut microbiota function, are associated with insulin resistance and higher risk of type 2 diabetes.

High levels of certain metabolites like BCAAs and imidazole propionate in your blood are linked to insulin resistance. These are partly produced by your gut bacteria, suggesting that a balanced diet supporting a healthy microbiome is important for metabolic health.

Newer GLP-1RAs achieve average weight loss of 15% or greater, but a substantial number of patients fail to achieve even 5% weight loss, and weight loss is lower in older adults, males, and those with type 2 diabetes.

If you are on a GLP-1RA and not losing weight, you are not alone. Older adults, men, and those with type 2 diabetes often lose less weight on average. Discuss this with your doctor to see if lifestyle adjustments or other strategies can help improve your response.